BRPI0415851A - medical uses of compounds exhibiting cb1 antagonistic activity and combination treatment involving said compounds - Google Patents
medical uses of compounds exhibiting cb1 antagonistic activity and combination treatment involving said compoundsInfo
- Publication number
- BRPI0415851A BRPI0415851A BRPI0415851-2A BRPI0415851A BRPI0415851A BR PI0415851 A BRPI0415851 A BR PI0415851A BR PI0415851 A BRPI0415851 A BR PI0415851A BR PI0415851 A BRPI0415851 A BR PI0415851A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- treatment
- prophylaxis
- young patients
- combination
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 238000011284 combination treatment Methods 0.000 title abstract 2
- 230000003042 antagnostic effect Effects 0.000 title 1
- 230000001747 exhibiting effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 4
- 238000011321 prophylaxis Methods 0.000 abstract 4
- 238000011282 treatment Methods 0.000 abstract 4
- 229940127470 Lipase Inhibitors Drugs 0.000 abstract 3
- 208000008589 Obesity Diseases 0.000 abstract 3
- 235000020824 obesity Nutrition 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- ZEWJFUNFEABPGL-UHFFFAOYSA-N 1,2,4-triazole-3-carboxamide Chemical class NC(=O)C=1N=CNN=1 ZEWJFUNFEABPGL-UHFFFAOYSA-N 0.000 abstract 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 1
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical class C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 abstract 1
- SIKWOTFNWURSAY-UHFFFAOYSA-N Lipstatin Natural products CCCCCCC1C(CC(CC=CCC=CCCCCC)C(=O)OC(CC(C)C)NC=O)OC1=O SIKWOTFNWURSAY-UHFFFAOYSA-N 0.000 abstract 1
- MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 abstract 1
- 229950002397 cetilistat Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 abstract 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 abstract 1
- 229960001243 orlistat Drugs 0.000 abstract 1
- -1 panclycines Chemical compound 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000007979 thiazole derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Virology (AREA)
- Rheumatology (AREA)
Abstract
"UTILIZAçõES MéDICAS DE COMPOSTOS QUE APRESENTAM ATIVIDADE ANTAGONìSTICA DE CB~ 1~ E TRATAMENTO DE COMBINAçãO ENVOLVENDO OS REFERIDOS COMPOSTOS". A presente invenção refere-se a uma nova utilização clínica de compostos com atividade no receptor CB~ 1~ selecionados a partir do grupo de derivados de 4,5-di-hidro-1H-pirazol, derivados de 1H-Imidazol, derivados de tiazol e/ou derivados de 1H-1,2,4-triazol-3-carboxamida, como cada um definido na descrição, ou de um seu pró-fármaco, um seu tautómero ou um seu sal, na preparação de medicamentos para o tratamento e/ou profilaxia de doenças relacionadas com o receptor CB~ 1~ em doentes jovens e/ou para o tratamento e/ou profilaxia da obesidade induzida por fármaco em doentes jovens, assim como em adolescentes. Além disso, a invenção refere-se à utilização dos referidos compostos com atividade no receptor CB~ 1~ em combinação com inibidores de lipase. Os referidos compostos são particularmente adequados em combinação com inibidores de lipase na preparação de medicamentos para o tratamento e/ou profilaxia da obesidade em pacientes adolescentes ou jovens e/ou para o tratamento e/ou profilaxia da obesidade induzida por fármaco em doentes jovens assim como em adolescentes. Os inibidores de lipase preferidos são orlistato, panclicinas, ATL-962 e/ou lipstatina."MEDICAL USES OF COMPOUNDS PRESENTING ANTAGONOSTIC ACTIVITY OF CB ~ 1 ~ AND COMBINATION TREATMENT INVOLVING THESE COMPOUNDS". The present invention relates to a novel clinical use of CB-1-receptor active compounds selected from the group of 4,5-dihydro-1H-pyrazole derivatives, 1H-Imidazole derivatives, thiazole derivatives and / or 1H-1,2,4-triazole-3-carboxamide derivatives as each defined in the description, or a prodrug thereof, a tautomer thereof or a salt thereof, in the preparation of medicaments for the treatment and / or prophylaxis of CB-1 receptor-related diseases in young patients and / or for the treatment and / or prophylaxis of drug-induced obesity in young patients, as well as adolescents. Furthermore, the invention relates to the use of said compounds with CB-1 receptor activity in combination with lipase inhibitors. Said compounds are particularly suitable in combination with lipase inhibitors in the preparation of medicaments for the treatment and / or prophylaxis of obesity in adolescent or young patients and / or for the treatment and / or prophylaxis of drug-induced obesity in young patients as well as in teenagers. Preferred lipase inhibitors are orlistat, panclycines, ATL-962 and / or lipstatin.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03103961 | 2003-10-24 | ||
EP03103967 | 2003-10-27 | ||
PCT/EP2004/052639 WO2005039550A2 (en) | 2003-10-24 | 2004-10-22 | Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0415851A true BRPI0415851A (en) | 2007-01-02 |
Family
ID=34524748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0415851-2A BRPI0415851A (en) | 2003-10-24 | 2004-10-22 | medical uses of compounds exhibiting cb1 antagonistic activity and combination treatment involving said compounds |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1753413A2 (en) |
JP (1) | JP2007513872A (en) |
AU (1) | AU2004283056A1 (en) |
BR (1) | BRPI0415851A (en) |
CA (1) | CA2543338A1 (en) |
MX (1) | MXPA06004434A (en) |
RU (1) | RU2006117627A (en) |
WO (1) | WO2005039550A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1575901B1 (en) | 2002-12-19 | 2012-10-10 | Merck Sharp & Dohme Corp. | Substituted amides |
AR046132A1 (en) * | 2003-10-24 | 2005-11-23 | Solvay Pharm Gmbh | PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST ONE COMPOUND WITH RECEIVER ACTIVITY OF CB1, OR A PROFARMACO, TAUTOMERO OR SALT OF THE SAME, AS A SUITABLE ACTIVE COMPONENT FOR THE TREATMENT AND / OR PROFILAXIS OF DISEASES RELATED TO THE RECEIVER CB1 IN PATIENTS OR YOUTH PATIENTS THE TREATMENT |
BRPI0515489A (en) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | heterocyclic derivatives and their use as stearoyl coat desaturase inhibitors |
JP5043668B2 (en) | 2004-09-20 | 2012-10-10 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | Heterocyclic derivatives and their use as therapeutic agents |
EP1807085B1 (en) | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
CA2580857A1 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
JP5094398B2 (en) | 2004-09-20 | 2012-12-12 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturases |
US7919496B2 (en) | 2004-09-20 | 2011-04-05 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes |
CN101083992A (en) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
WO2007130075A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
EP1921073A1 (en) | 2006-11-10 | 2008-05-14 | Laboratorios del Dr. Esteve S.A. | 1,2,4-Triazole derivatives as sigma receptor inhibitors |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3003148B2 (en) * | 1989-01-05 | 2000-01-24 | 藤沢薬品工業株式会社 | Thiazole compound, process for producing the same, and pharmaceutical composition containing the same |
JPH10504542A (en) * | 1994-07-27 | 1998-05-06 | ジー.ディー.サール アンド カンパニー | Substituted thiazole compounds for treating inflammation |
US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US6492516B1 (en) * | 1999-05-14 | 2002-12-10 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
DE60202270T2 (en) * | 2001-03-22 | 2005-05-19 | Solvay Pharmaceuticals B.V. | 4,5-Dihydro-1H-pyrazole derivatives with CB1-antagonistic activity |
AU2002333853B2 (en) * | 2001-09-21 | 2006-07-13 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity |
UA78523C2 (en) * | 2001-09-21 | 2007-04-10 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazoie derivatives as cb1 antagonists |
TWI231757B (en) * | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
AR036608A1 (en) * | 2001-09-24 | 2004-09-22 | Bayer Corp | IMIDAZOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF OBESITY |
US20050004134A1 (en) * | 2001-11-08 | 2005-01-06 | Hideo Tsutsumi | Thiazole derivative and pharmaceutical use thereof |
TW200407110A (en) * | 2001-11-23 | 2004-05-16 | Astrazeneca Ab | New use for the treatment of gastroesophageal reflux disease |
US20040248956A1 (en) * | 2002-01-29 | 2004-12-09 | Hagmann William K | Substituted imidazoles as cannabinoid receptor modulators |
AR038966A1 (en) * | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | DERIVATIVES OF TIAZOL THAT HAVE ANTAGONIST, AGONIST OR PARTIAL AGONIST ACTIVITY OF CB1 |
TW200412942A (en) * | 2002-08-06 | 2004-08-01 | Abbott Lab | Appetite control method |
AR041268A1 (en) * | 2002-09-19 | 2005-05-11 | Solvay Pharm Bv | DERIVED FROM 1H -1,2,4- TRIAZOL-3-CARBOXAMIDE THAT HAVE AGONIST, PARTIAL AGONIST, INVESTED AGONIST OR ANTAGONIST RECEIVER OF CANNABINOID CB 1 AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
GB0230087D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
-
2004
- 2004-10-22 CA CA002543338A patent/CA2543338A1/en not_active Abandoned
- 2004-10-22 AU AU2004283056A patent/AU2004283056A1/en not_active Abandoned
- 2004-10-22 MX MXPA06004434A patent/MXPA06004434A/en not_active Application Discontinuation
- 2004-10-22 WO PCT/EP2004/052639 patent/WO2005039550A2/en active Application Filing
- 2004-10-22 BR BRPI0415851-2A patent/BRPI0415851A/en not_active IP Right Cessation
- 2004-10-22 EP EP04817279A patent/EP1753413A2/en not_active Withdrawn
- 2004-10-22 RU RU2006117627/04A patent/RU2006117627A/en not_active Application Discontinuation
- 2004-10-22 JP JP2006536096A patent/JP2007513872A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2005039550A2 (en) | 2005-05-06 |
AU2004283056A1 (en) | 2005-05-06 |
MXPA06004434A (en) | 2006-06-20 |
RU2006117627A (en) | 2007-12-10 |
CA2543338A1 (en) | 2005-05-06 |
JP2007513872A (en) | 2007-05-31 |
WO2005039550A3 (en) | 2007-03-22 |
EP1753413A2 (en) | 2007-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0415421A (en) | sulfoximine-substituted pyrimidines as cdk and / or vegf inhibitors, their preparation and their use as a medicament | |
BRPI0511874A (en) | pyrrolopyridine derivatives | |
BRPI0606930A2 (en) | compound or a pharmaceutically acceptable salt thereof, process for preparing a compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, use of a compound or a pharmaceutically acceptable salt thereof, and methods for producing a drug inhibiting effect. b-raf in a warm-blooded animal, for producing an anti-cancer effect on a warm-blooded animal and for treating diseases of an animal in a warm-blooded animal | |
BRPI0410563A (en) | Process pyrazole quinazoline derivatives for their preparation and their use as kinase inhibitors | |
NO341617B1 (en) | Dihydropyrazole pyrimidinone derivatives, their use in therapy and in the treatment of cancer, their use in the manufacture of a medicament, and in use as a radiation sensitizer, their pharmaceutical composition, and a combined preparation for administration in the treatment of cancer. | |
BRPI0606313A2 (en) | 4- (1h-indol-3-yl) -pyrimidin-2-ylamine derivatives, process for their preparation and use in therapy | |
BRPI0511741A (en) | quinazoline derivative or a pharmaceutically acceptable salt thereof, pharmaceutical composition, process for preparing a quinazoline derivative or a pharmaceutically acceptable salt thereof | |
BR0312464A (en) | Tyrosine kinase inhibitors | |
BRPI0512588A (en) | pyrimidine urea derivatives as kinase inhibitors | |
BRPI0515489A (en) | heterocyclic derivatives and their use as stearoyl coat desaturase inhibitors | |
BRPI0606397B8 (en) | 1-thio-d-glucitol derivatives, method of producing them and pharmaceutical product containing them. | |
BRPI0413860A (en) | [1,8] Naphthyridin-2-ones and related compounds for the treatment of schizophrenia. | |
BR0312957A (en) | A compound or a pharmaceutically acceptable salt thereof, use thereof, pharmaceutical composition, and method for producing an inhibitory effect of 11betahsd1 on a warm-blooded animal such as man in need of such treatment. | |
WO2007007919A3 (en) | Heterocyclic janus kinase 3 inhibitors | |
BRPI0411155A (en) | compound that binds to and activates the erythropoietin receptor, pharmaceutical composition and its use | |
BRPI0415851A (en) | medical uses of compounds exhibiting cb1 antagonistic activity and combination treatment involving said compounds | |
BRPI0411863A (en) | pyrazolyl indole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
BR0315797A (en) | Mch antagonist-effective amide compounds, and drugs containing such compounds | |
BRPI0412527A (en) | compound, use thereof, pharmaceutical composition, aerosol pharmaceutical formulation, method for treating a human or animal patient with an anti-inflammatory and / or allergic condition, and process for preparing a compound. | |
BR0316081A (en) | 2-Pyridone Derivatives as Neutrophil Elastase Inhibitors | |
BRPI0414532A (en) | compound, process for preparing same, pharmaceutical composition, use of a compound, and method for producing an antiproliferative effect on a warm-blooded animal | |
BRPI0511778A (en) | mothball derivatives useful as histamine receptor 3 ligands | |
BRPI0411017A (en) | 3-substituted indoles and derivatives thereof as therapeutic agents | |
BRPI0519351A2 (en) | medicines for the treatment or prevention of fibrotic diseases | |
BR0314635A (en) | Pyridine derivatives as cb2 receptor modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 6A E 7A ANUIDADE(S) |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. |